🚀 VC round data is live in beta, check it out!
Nicox Valuation Multiples
Discover revenue and EBITDA valuation multiples for Nicox and similar public comparables like Xilio Therapeutics, Cessatech, Rein Therapeutics, Telomir Pharmaceuticals and more.
Nicox Overview
About Nicox
Nicox SA is an international ophthalmology company developing solutions to help maintain vision and improve ocular health. Its program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Its first product, VYZULTA in glaucoma, licensed exclusively to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE in allergic conjunctivitis, licensed in multiple geographies.
Founded
1996
HQ
Employees
14
Website
Sectors
Financials (LTM)
EV
$60M
Nicox Financials
Nicox reported last 12-month revenue of $20M.
In the same LTM period, Nicox generated $3M in net income.
Revenue (LTM)
Nicox P&L
In the most recent fiscal year, Nicox reported revenue of $9M and EBITDA of ($24M).
Nicox expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $20M | XXX | $9M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $8M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 86% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($24M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (262%) | XXX | XXX | XXX |
| EBIT Margin | 32% | XXX | (124%) | XXX | XXX | XXX |
| Net Profit | $3M | XXX | ($26M) | XXX | XXX | XXX |
| Net Margin | 17% | XXX | (285%) | XXX | XXX | XXX |
| Net Debt | — | — | $5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Nicox Stock Performance
Nicox has current market cap of $50M, and enterprise value of $60M.
Market Cap Evolution
Nicox's stock price is $0.48.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $60M | $50M | -0.5% | XXX | XXX | XXX | $-0.26 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNicox Valuation Multiples
Nicox trades at 3.0x EV/Revenue multiple, and (2.5x) EV/EBITDA.
EV / Revenue (LTM)
Nicox Financial Valuation Multiples
As of April 18, 2026, Nicox has market cap of $50M and EV of $60M.
Equity research analysts estimate Nicox's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nicox has a P/E ratio of 14.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $50M | XXX | $50M | XXX | XXX | XXX |
| EV (current) | $60M | XXX | $60M | XXX | XXX | XXX |
| EV/Revenue | 3.0x | XXX | 6.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (2.5x) | XXX | XXX | XXX |
| EV/EBIT | 9.1x | XXX | (5.3x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 7.6x | XXX | XXX | XXX |
| P/E | 14.3x | XXX | (1.9x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Nicox Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Nicox Margins & Growth Rates
Nicox's revenue in the last 12 month grew by 16%.
Nicox's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $1.4M for the same period.
Nicox Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 106% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (262%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 25% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.4M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 12% | XXX | 54% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 56% | XXX | 76% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 210% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Nicox Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Nicox | XXX | XXX | XXX | XXX | XXX | XXX |
| Xilio Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cessatech | XXX | XXX | XXX | XXX | XXX | XXX |
| Rein Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Telomir Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Labiana Health | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nicox M&A Activity
Nicox acquired XXX companies to date.
Last acquisition by Nicox was on XXXXXXXX, XXXXX. Nicox acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Nicox
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNicox Investment Activity
Nicox invested in XXX companies to date.
Nicox made its latest investment on XXXXXXXX, XXXXX. Nicox invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Nicox
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Nicox
| When was Nicox founded? | Nicox was founded in 1996. |
| Where is Nicox headquartered? | Nicox is headquartered in France. |
| How many employees does Nicox have? | As of today, Nicox has over 14 employees. |
| Is Nicox publicly listed? | Yes, Nicox is a public company listed on Euronext Paris. |
| What is the stock symbol of Nicox? | Nicox trades under ALCOX ticker. |
| When did Nicox go public? | Nicox went public in 1999. |
| Who are competitors of Nicox? | Nicox main competitors are Xilio Therapeutics, Cessatech, Rein Therapeutics, Telomir Pharmaceuticals. |
| What is the current market cap of Nicox? | Nicox's current market cap is $50M. |
| What is the current revenue of Nicox? | Nicox's last 12 months revenue is $20M. |
| What is the current revenue growth of Nicox? | Nicox revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of Nicox? | Current revenue multiple of Nicox is 3.0x. |
| Is Nicox profitable? | Yes, Nicox is net-income-positive (as of the last 12 months). |
| What is the current net income of Nicox? | Nicox's last 12 months net income is $3M. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.